Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Department of Urology, Konyang University College of Medicine, Daejeon, Korea.
Prostate. 2019 Dec;79(16):1805-1810. doi: 10.1002/pros.23905. Epub 2019 Sep 4.
Recently, a new prostate cancer (PC) grading system was introduced, where Gleason score (GS) 7 was divided into 3 + 4 = 7 and 4 + 3 = 7 due to the different prognoses associated with each tumor type. However, whether downgrading or upgrading from needle biopsy (NB) to radical prostatectomy (RP) affects oncologic outcomes is currently unknown. Herein, we investigated the prognostic impact of downgrading and upgrading from NB to RP among men with GS 7 PC.
We retrospectively reviewed the medical records of 3003 patients with localized PC who underwent RP between 2005 and 2014. We included 692 patients with GS 7 PC on both NB and RP specimens. We analyzed the data using Kaplan-Meier methods and Cox proportional hazard models.
Of the 692 patients enrolled in this study, 389 (56.2%) and 303 (43.8%) patients had RP GS 3 + 4 = 7 and RP GS 4 + 3 = 7 PC, respectively. On the basis of NB and RP GS, 264 (38.1%), 125 (18.1%), 142 (20.5%), and 161 (23.3%) patients were classified as 3 + 4/3 + 4, 4 + 3/3 + 4, 3 + 4/4 + 3, and 4 + 3/4 + 3, respectively. Kaplan-Meier curves showed significant differences in biochemical recurrence (BCR)-free survival across the groups (P < .001). In the multivariate analyses, these groups were significantly associated with BCR (4 + 3/3 + 4: hazard ratio [HR], 1.675; 3 + 4/4 + 3: HR, 1.908; and 4 + 3/4 + 3: HR, 2.699).
Downgrading and upgrading from NB to RP was an independent predictor of BCR in men with GS 7 PC, which could be due to the amount of Gleason pattern 4.
最近,引入了一种新的前列腺癌(PC)分级系统,由于每种肿瘤类型的预后不同,Gleason 评分(GS)7 分为 3+4=7 和 4+3=7。然而,从针吸活检(NB)到根治性前列腺切除术(RP)的降级或升级是否会影响肿瘤学结果目前尚不清楚。在此,我们研究了 GS 7 PC 患者从 NB 到 RP 降级和升级对预后的影响。
我们回顾性分析了 2005 年至 2014 年间接受 RP 治疗的 3003 例局限性 PC 患者的病历。我们纳入了 NB 和 RP 标本均为 GS 7 PC 的 692 例患者。我们使用 Kaplan-Meier 方法和 Cox 比例风险模型分析数据。
本研究纳入的 692 例患者中,389 例(56.2%)和 303 例(43.8%)患者的 RP GS 为 3+4=7 和 RP GS 为 4+3=7 PC。根据 NB 和 RP GS,264 例(38.1%)、125 例(18.1%)、142 例(20.5%)和 161 例(23.3%)患者分别被分类为 3+4/3+4、4+3/3+4、3+4/4+3 和 4+3/4+3。Kaplan-Meier 曲线显示各组之间在生化复发(BCR)无复发生存方面有显著差异(P<.001)。在多变量分析中,这些组与 BCR 显著相关(4+3/3+4:风险比[HR],1.675;3+4/4+3:HR,1.908;4+3/4+3:HR,2.699)。
从 NB 到 RP 的降级和升级是 GS 7 PC 患者 BCR 的独立预测因素,这可能是由于 Gleason 模式 4 的数量所致。